Quantitative and Systems Pharmacology in the Post-genomic Era: New Approaches to Discovering Drugs and Understanding Therapeutic Mechanisms

November 2, 2011

This white paper arises from two workshops held at the NIH to review the state of the art in systems biology and pharmacology. Workshop participants included leaders in the two fields working in academia, industry and government (including the FDA). They asked whether a merger of systems biology and pharmacology via the emerging discipline of Quantitative and Systems Pharmacology (QSP) could advance the discovery, development and clinical use of therapeutic drugs. Preparing the White Paper involved a year of consultation with a diverse community of academic, industrial and government scientists but the views expressed herein are solely those of the authors.

Spotlight

Orion Clinical

Simbec-Orion Group is a full-service, boutique CRO which offers specialist expertise in oncology, rare & orphan diseases, dermatology, respiratory, neurology and infectious diseases and translational medicine. We offer our clients a full spectrum of drug development services from first-in-human Phase I clinical studies through to pivotal Phase III studies and Phase IV post marketing studies. We have expertise in all drug types, dosage forms and delivery mechanisms. Simbec-Orion Group supports its clients’ development programmes with our in-house central laboratories, pharmacovigilance, data management and statistics, IMP management/pharmacy and medical management.

OTHER WHITEPAPERS
news image

Infosys and Top Pharma Bring Digital Transformation to DrugManufacturing Data

whitePaper | April 1, 2022

In 2017, a top 20 global pharmaceutical company began a journey to digitally transform its pharmaceutical engineering and manufacturing capabilities by constructing a data integration and visualization platform, with strategic assistance and technical implementation provided by its partner Infosys.

Read More
news image

Asia Pacific as a Clinical Trials Powerhouse

whitePaper | October 6, 2022

Patient availability is a critical component for clinical trials, and so it stands to reason that clinical development should match the epidemiology of diseases. Of course, this is often not the case,

Read More
news image

U.S. Pharmaceutical Market Trend Report

whitePaper | February 28, 2022

Starting in Week 9 of 2020, prescription volume and claims data entered a period of intense volatility, followed by a steady state

Read More
news image

Essential for Stable U.S. Supply Chains of Quality Pharmaceuticals

whitePaper | May 11, 2022

CDER is taking another step towards realizing the vision for pharmaceutical quality in the 21st century: a maximally efficient, agile, flexible manufacturing sector that reliably produces high-quality drug products without extensive regulatory oversight.

Read More
news image

THE PHARMACEUTICAL INDUSTRY AND GLOBAL HEALTH

whitePaper | January 31, 2022

COVID-19 is an infectious disease caused by a newly discovered coronavirus, which was first identified in December 2019.

Read More
news image

Why Deck 7

whitePaper | January 1, 2020

With over 2,800 campaigns each year delivered through a team of 300+ digital, data, and technology specialists, Deck 7 is a first resource for B2B demand generation services for marketers worldwide. Clients leverage Deck 7’s multichannel content marketing services and Media 7’s network of 30+ online publications for content syndication to engage over 95 million buyers across 16 industries and 120+ countries.

Read More

Spotlight

Orion Clinical

Simbec-Orion Group is a full-service, boutique CRO which offers specialist expertise in oncology, rare & orphan diseases, dermatology, respiratory, neurology and infectious diseases and translational medicine. We offer our clients a full spectrum of drug development services from first-in-human Phase I clinical studies through to pivotal Phase III studies and Phase IV post marketing studies. We have expertise in all drug types, dosage forms and delivery mechanisms. Simbec-Orion Group supports its clients’ development programmes with our in-house central laboratories, pharmacovigilance, data management and statistics, IMP management/pharmacy and medical management.

Events